Triglyceride as a risk factor for coronary artery disease

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 2, 1998, Pages 22-25

  Gotto Jr , Antonio M ^a   Jou, Jesse ^b  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATIN; TRIACYLGLYCEROL;

ATHEROGENESIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION FUNCTION; EXERCISE; HIGH RISK POPULATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; NIACIN; RISK FACTORS; TRIGLYCERIDES;

EID: 0032511997     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(98)00770-x     Document Type: Article

References (26)

1. Hulley SB. Epidemiology as a guide to clinical decisions. The associations between triglyceride and coronary heart disease. N Engl J Med 1980;302:1383-1389.
2. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70(suppl):3H-9H.
3. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibault N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-304.
4. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-1036.
5. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-229.
6. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997;95:1-4.
7. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
8. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
9. Assman G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184.
10. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
11. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progress of atherosclerotic lesions are determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-722.
12. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
13. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr. Familial apolipoprotein E deficiency. J Clin Invest 1986;78:1206-1219.
14. Mahley RW, Rail SC Jr. Type II hyperlipidemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR. Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarde JB, Fredickson DS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995:1953-1980.
15. Gianturco SH, Ramprasad MP, Lin AH, Song R, Bradley WA. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J Lip id Res 1994;35:1674-1687.
16. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1997;106:83-97.
17. Patsch JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, Gotto AM, Patsch W. Relation of triglyceride metabolism and coronary heart disease: Studies in a postprandial state. Arterioscler Thromb Vasc Biol 1992;12:1336-1345.
18. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997;79:350-354.
19. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997;278:1682-1686.
20. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1995;15:2122-2129.
21. Johansson JO, Egberg N, Asplund-Carlson A, Carlson LA. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk 1997;4:165-171.
22. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
23. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
24. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
25. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81(suppl):66B-69B.
26. Vega GL, Grundy SM. Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81(suppl):36B-42B.